What type of study is this?

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

View Full Paper

Ask AI

Bookmark

Authors

Phase 3 SUNMO trial shows enhanced overall response and progression-free survival in LBCL patients, indicating new treatment potential.

Mosun-Pola showed significantly longer progression-free survival than R-GemOx at 11.5 months vs. 3.8 months.
The overall response rate was significantly higher with Mosun-Pola at 70% compared to 40% for R-GemOx.
Grade ≥2 cytokine release syndrome occurred in less than 5% of patients receiving Mosun-Pola.
Patient-reported outcomes improved in patients treated with Mosun-Pola compared to those receiving R-GemOx.

Budde et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark